Coherus BioSciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Coherus BioSciences, Inc. (CHRS) on April 1, 2025, covering events occurring on March 31, 2025. The filing details significant corporate actions related to the divestiture of the UDENYCA franchise and the restructuring of the company's debt obligations.
Key Financial Metrics and Debt Structure
The filing focuses on debt management rather than operational financial performance metrics such as revenue or cash flow, which are not provided in this document.
- Convertible Notes Repurchase: The Company agreed to repurchase approximately $170 million aggregate principal amount of its 1.500% Convertible Senior Subordinated Notes due 2026.
- Repurchase Price: The repurchase price is 100% of the principal amount plus accrued and unpaid interest.
- Remaining Debt: Following the repurchase, approximately $60 million aggregate principal amount of Convertible Notes will remain outstanding.
- Future Repurchase Plan: Upon closing the UDENYCA transaction, the Company intends to offer to repurchase the remaining $60 million of notes at 100% of principal plus accrued interest under the Fundamental Change Repurchase Right.
Material Changes and Transactions
The filing reports two primary material events:
- Asset Divestiture: On December 2, 2024, the Company entered into an Asset Purchase Agreement to divest its UDENYCA (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals Ltd. This transaction is a condition precedent for the debt repurchases.
- Indenture Amendment: On March 31, 2025, the Company entered into a First Supplemental Indenture to amend the terms of its Convertible Notes. This amendment was necessary to permit the UDENYCA divestiture transaction and received consent from holders of a majority of the outstanding notes.
Outlook, Risks, and Contingencies
The debt repurchases are explicitly conditioned upon the closing of the UDENYCA divestiture transaction. The filing notes that the Company intends to utilize the Fundamental Change Repurchase Right to retire the remaining debt following the asset sale. No specific guidance on future revenue or earnings is provided in this report.
Key Facts for Investor Verification
- Verify the closing status of the UDENYCA franchise sale to Intas Pharmaceuticals Ltd., as the $170 million debt repurchase is contingent upon this event.
- Confirm the final amount of Convertible Notes remaining outstanding after the initial $170 million repurchase and the subsequent Fundamental Change Repurchase offer.
- Review the First Supplemental Indenture (Exhibit 4.1) for specific terms regarding the amendments to the Convertible Notes.
- Monitor the press release (Exhibit 99.1) for further details on the privately negotiated repurchase transactions.